Cencora, Inc. (NYSE:COR) Shares Acquired by Oregon Public Employees Retirement Fund

Oregon Public Employees Retirement Fund raised its stake in shares of Cencora, Inc. (NYSE:COR) by 0.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 15,051 shares of the company’s stock after buying an additional 120 shares during the period. Oregon Public Employees Retirement Fund’s holdings in Cencora were worth $3,382,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Venturi Wealth Management LLC raised its position in Cencora by 1.0% in the third quarter. Venturi Wealth Management LLC now owns 4,447 shares of the company’s stock worth $1,001,000 after acquiring an additional 46 shares in the last quarter. Prime Capital Investment Advisors LLC increased its holdings in shares of Cencora by 1.2% in the third quarter. Prime Capital Investment Advisors LLC now owns 3,768 shares of the company’s stock valued at $848,000 after buying an additional 46 shares in the last quarter. Shepherd Financial Partners LLC lifted its position in shares of Cencora by 0.9% during the 4th quarter. Shepherd Financial Partners LLC now owns 5,441 shares of the company’s stock valued at $1,223,000 after acquiring an additional 46 shares during the last quarter. WASHINGTON TRUST Co boosted its stake in shares of Cencora by 37.7% during the 4th quarter. WASHINGTON TRUST Co now owns 168 shares of the company’s stock worth $38,000 after acquiring an additional 46 shares in the last quarter. Finally, JFS Wealth Advisors LLC grew its holdings in shares of Cencora by 63.0% in the 4th quarter. JFS Wealth Advisors LLC now owns 119 shares of the company’s stock worth $27,000 after acquiring an additional 46 shares during the last quarter. 97.52% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have issued reports on COR. UBS Group boosted their price objective on Cencora from $275.00 to $285.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. JPMorgan Chase & Co. boosted their price target on shares of Cencora from $289.00 to $301.00 and gave the company an “overweight” rating in a report on Friday, January 24th. Evercore ISI increased their price objective on Cencora from $270.00 to $280.00 and gave the stock an “outperform” rating in a research note on Thursday, February 6th. Wells Fargo & Company raised their price target on shares of Cencora from $237.00 to $251.00 and gave the stock an “equal weight” rating in a report on Wednesday, January 29th. Finally, Robert W. Baird upped their target price on Cencora from $287.00 to $292.00 and gave the stock an “outperform” rating in a research report on Thursday, November 7th. Two research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $277.90.

Insider Activity

In other Cencora news, EVP Silvana Battaglia sold 5,000 shares of the company’s stock in a transaction on Friday, February 21st. The stock was sold at an average price of $242.24, for a total transaction of $1,211,200.00. Following the transaction, the executive vice president now owns 15,374 shares of the company’s stock, valued at approximately $3,724,197.76. This represents a 24.54 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 10.80% of the stock is owned by insiders.

Cencora Trading Down 0.8 %

Shares of COR stock opened at $248.71 on Friday. The stock has a market cap of $48.23 billion, a price-to-earnings ratio of 35.38, a P/E/G ratio of 1.31 and a beta of 0.49. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92. The firm has a fifty day moving average of $240.74 and a 200-day moving average of $237.66. Cencora, Inc. has a 52-week low of $214.77 and a 52-week high of $262.26.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. On average, equities research analysts forecast that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, March 3rd. Stockholders of record on Friday, February 14th will be given a dividend of $0.55 per share. The ex-dividend date is Friday, February 14th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.88%. Cencora’s payout ratio is 31.29%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.